Trial Profile
A Prospective, Randomized, Multicenter, Comparative, Openlabel, Parallel study to evaluate the Efficacy, Safety and Pharmacokinetics of Test-Trastuzumab Emtansine (ZRC- 3256;Cadila Healthcare Ltd) and Reference-Trastuzumab Emtansine(Kadcyla, Roche Products (India) Pvt. Ltd.) in HER2- Positive Metastatic Breast Cancer Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jun 2020
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Cadila Healthcare
- 19 May 2020 Status changed from not yet recruiting to completed.
- 13 Nov 2018 New trial record